BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 16845332)

  • 1. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
    Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
    Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
    Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
    Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
    Weber RW; O'Day S; Rose M; Deck R; Ames P; Good J; Meyer J; Allen R; Trautvetter S; Timmerman M; Cruickshank S; Cook M; Gonzalez R; Spitler LE
    J Clin Oncol; 2005 Dec; 23(35):8992-9000. PubMed ID: 16260693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S
    Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
    J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
    Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
    Ron IG; Sarid D; Ryvo L; Sapir EE; Schneebaum S; Metser U; Asna N; Inbar MJ; Safra T
    Melanoma Res; 2006 Feb; 16(1):65-9. PubMed ID: 16432458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
    J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
    de Gast GC; Batchelor D; Kersten MJ; Vyth-Dreese FA; Sein J; van de Kasteele WF; Nooijen WJ; Nieweg OE; de Waal MA; Boogerd W
    Br J Cancer; 2003 Jan; 88(2):175-80. PubMed ID: 12610499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
    Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS
    J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
    Alrwas A; Papadopoulos NE; Cain S; Patel SP; Kim KB; Deburr TL; Bassett R; Hwu WJ; Bedikian AY; Davies MA; Woodman SE; Hwu P
    Melanoma Res; 2014 Aug; 24(4):342-8. PubMed ID: 24743052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
    Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
    Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
    Yoon C; Papadopoulos NE; Camacho LH; McIntyre S; Alvarado GC; Bedikian AY; Hwu P; Kim KB
    Melanoma Res; 2010 Feb; 20(1):43-7. PubMed ID: 19952963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.